Dr. Andreas Marzinzik

Novartis S.A., Basel, CH

Toward the goal of curing CML: Discovery of ABL001,

a novel allosteric inhibitor of BCR-ABL

December 4th, 18:15,  IAAC Lecture Hall Humboldt Str. 8